Abstract 507P
Background
Neuroblastoma is the most common extracranial solid tumor of childhood accounting for 10% of childhood cancers with a median age of diagnosis of 19 months. Outcomes of the disease show a varied presentation from spontaneous regression to fatal death.
Methods
This is a single centre observational study of 114 patients admitted in regional cancer centre, in South India from April 2014 to April 2020. Baseline characteristics noted and disease was risk stratified accordingly. Patients were treated based on age at presentation and resectability of disease. Patients < 6 months were observed for spontaneous regression. Older patients with potentially resectable disease received NACT with CADO protocol followed by surgery and Adjuvant chemotherapy. All stage IV patients received RAPID COJEC protocol followed by Autologous BMT (if complete metabolic response achieved). OS at the end of 2 years was measured.
Results
Among 114 patients, 40.3% were male and 59.7% were female. Patients with age <1 yr., 1-5 yr., and > 5 yr. were 15.7%, 57.8%, and 26.3% respectively. The commonest primary site of presenting mass was in abdomen, left suprarenal mass in 42 cases (36.84%) and right suprarenal mass in 28 cases (24.56%). Proptosis and raccoon eyes were seen in 13 cases (11.40%). OMAS (8 cases) & VIP syndrome (3 cases) were the most common paraneoplastic syndromes. The commonest histopathology was neuroblastoma (82%), followed by ganglioneuroblastoma. The OS at 2 yrs. was 34.8%, 56.25%, and 75% among high risk, intermediate-risk, and low-risk groups respectively.
Conclusions
Gratifying advances in the treatment of paediatric cancers for the past three decades have resulted in a decrease in annual mortality. Though the clinicopathological profile was more in line with western data, the outcomes were different in our centre possibly due to delay in presentation as well as poor adherence to treatment. The delay and fallouts were secondary to poor socioeconomic status and low literacy of majority of patients who present to our hospital (95%). As with other cancers it can be concluded that the outcomes would improve by increasing awareness for a prompt institutional care especially in developing countries.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
MNJ Institute of Oncology and Regional Cancer Centre.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.